When was Rapafusyn founded?

Rapafusyn was founded in 2015 and raised its 1st funding round 9 years after it was founded.

Where is Rapafusyn located?

Rapafusyn is headquartered in Baltimore, United States.

How many employees does Rapafusyn have?

As of Jun 30, 2026, the latest employee count at Rapafusyn is 21.

Is Rapafusyn a funded company?

Rapafusyn is a funded company, having raised a total of $44M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 20, 2024.

When was the latest funding round of Rapafusyn?

Rapafusyn's latest funding was a $***** Series A round on Sep 05, 2025, with participation from 5 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.85B in funding in 2026 to date.

Where does Rapafusyn rank among its competitors?

Rapafusyn ranks 420th amongst 3530 active competitors, of which 1212 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Rapafusyn?

Rapafusyn's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Rapafusyn - 2026 Company Profile, Team, Funding & Competitors

Rapafusyn is a series A company based in Baltimore (United States), founded in 2015. It operates as a Developer of therapeutics for treatment of multiple diseses. Rapafusyn has raised $44M in funding from 3E Bioventures Capital and Proxima Ventures. The company has 3530 active competitors, including 1212 funded and 823 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutics for treatment of multiple diseses. It offers platform that screens libraries of hybrid macrocycles to discover lead compound rapafucin-FKBP complexes against novel and validated targets which include oncology, immunosuppression, ischemic reperfusion injury, and neurodegenerative diseases.

Website: rapafusyn.com
Social
Email ID: *****@rapafusyn.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Baltimore, United States

Stage

Series A

Total Funding

$44M in 2 rounds

Latest Funding Round

Series A, Sep 05, 2025, $*****

Investors

3E Bioventures Capital & 4 more

Ranked

420^th among 3530 active competitors

Employee Count

21 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3304 more

View Rapafusyn's full profile

Rapafusyn has raised a total funding of $44M over 2 rounds. Its first funding round was on Jun 20, 2024. Its latest funding round was a Series A round on Sep 05, 2025 for $*****. 5 investors participated in its latest round. Rapafusyn has 5 institutional investors.

Here is the list of recent funding rounds of Rapafusyn:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2025	5126185	Series A	1958524	4030361	2058344	7302106
Jun 20, 2024	2820616	Series A	3394898	2043520	3E Bioventures Capital & 1 more	Lapam Capital

Access funding benchmarks and valuations. Sign up today!

View details of Rapafusyn's funding rounds and investors

Rapafusyn's employee count trend

Rapafusyn has 21 employees as of Jun 26. Here is Rapafusyn's employee count trend over the years:

Uncover Rapafusyn's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rapafusyn include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Rapafusyn, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
420th	Rapafusyn 2015, Baltimore (United States), Series A	Developer of therapeutics for treatment of multiple diseses	$44M	3E Bioventures Capital, Yonjin Capital & 3 others	55/100